OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
Companies/Health Care/MRK
MRKNYSE$111.2664

Merck & Co., Inc.

PharmaceuticalsVerified

Merck & Co., Inc. (MRK) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 136,866,000,000 USD, total equity 52,606,000,000, short-term debt 2,300,000,000, long-term debt 46,750,000,000. Net cash position is approximately -34,485,000,000 USD. Self-calculated market cap is 278,928,820,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 65,011,000,000, gross profit 0, operating income 0, net income 18,254,000,000. Return on equity ~34.7%. Return on assets ~13.3%. Operating-cash-flow to net-income ratio is 0.90. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk..

30-day price · MRK-3.48 (-3.0%)
Low$107.40High$124.00Close$112.56As of18 May, 00:00 UTC
Profile
CompanyMerck & Co., Inc.
ExchangeNYSE
TickerMRK
CIK0000310158
SICPharmaceutical Preparations
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Merck & Co., Inc. is classified under Healthcare / Pharmaceuticals and appears profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.92 based on verified market data; matched terms: Pharmaceuticals, Pharmaceuticals & Medical Research, Healthcare.

Merck & Co., Inc. (MRK) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 136,866,000,000 USD, total equity 52,606,000,000, short-term debt 2,300,000,000, long-term debt 46,750,000,000. Net cash position is approximately -34,485,000,000 USD. Self-calculated market cap is 278,928,820,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 65,011,000,000, gross profit 0, operating income 0, net income 18,254,000,000. Return on equity ~34.7%. Return on assets ~13.3%. Operating-cash-flow to net-income ratio is 0.90. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk..
Key takeaways
  • Observed GAAP P/E is about 15.28x.
  • Return on equity is about 34.7%.
  • Debt to equity is about 0.93x.
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$65.01B
Gross profit—
Operating income—
Net income$18.25B
R&D$15.79B
SG&A—
D&A—
SBC$820.0M
Operating cash flow$16.47B
CapEx$4.11B
Free cash flow$12.36B
Total assets$136.87B
Total liabilities—
Total equity$52.61B
Cash & equivalents$14.56B
Long-term debt$46.75B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$65.01B—$18.25B$12.36B
FY2024$64.17B—$17.12B$18.10B
FY2025$64.17B—$17.12B$18.10B
FY2023$60.12B—$365.0M—
FY2024$60.12B—$365.0M$9.14B
PeriodGross %Op %Net %FCF %
FY2025————
FY2024————
FY2025————
FY2023————
FY2024————
PeriodAssetsEquityCashDebt
FY2025$136.87B$52.61B$14.56B—
FY2024$117.11B$46.31B$13.24B—
FY2025$117.11B$46.31B$13.24B—
FY2023$106.67B$37.58B$6.84B—
FY2024$106.67B$37.58B$6.84B—
PeriodOCFCapExFCFSBC
FY2025$16.47B$4.11B$12.36B$820.0M
FY2024$21.47B$3.37B$18.10B$761.0M
FY2025$21.47B$3.37B$18.10B$761.0M
FY2023—$3.86B—$645.0M
FY2024$13.01B$3.86B$9.14B$645.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$48.61B—$15.29B$10.54B
Q2 2025$31.34B—$9.51B$3.70B
Q3 2025————
Q1 2025$15.53B—$5.08B$1.17B
PeriodGross %Op %Net %FCF %
Q3 2025————
Q2 2025————
Q3 2025————
Q1 2025————
PeriodAssetsEquityCashDebt
Q3 2025$129.55B$51.85B$18.17B—
Q2 2025$117.52B$48.99B$8.01B—
Q3 2025—$49.06B——
Q1 2025$115.12B$48.34B$8.63B—
PeriodOCFCapExFCFSBC
Q3 2025$13.62B$3.08B$10.54B$615.0M
Q2 2025$5.79B$2.09B$3.70B$411.0M
Q3 2025————
Q1 2025$2.50B$1.33B$1.17B$195.0M
Valuation
Market price$111.26
Market cap$278.93B
Enterprise value$313.41B
P/E15.3
Reported non-GAAP P/E—
EV/Revenue4.8
EV/Op income—
EV/OCF19.0
P/B—
P/Tangible book—
Tangible book—
Net cash-$34.48B
Current ratio1.5
Debt/Equity0.9
ROA13.3%
ROE34.7%
Cash conversion90.0%
CapEx/Revenue6.3%
SBC/Revenue1.3%
Asset intensity0.2
Dilution ratio—
Risk assessment
Dilution riskMedium
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricMRKActivity
Op margin—18.2% medp25 18.2% · p75 24.6%
Net margin28.1%14.7% medp25 11.7% · p75 28.1%top quartile
Gross margin—19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3%24.3% medp25 6.6% · p75 24.3%top quartile
CapEx / revenue6.3%4.9% medp25 4.2% · p75 6.3%top quartile
Debt / equity93.0%71.3% medp25 19.0% · p75 91.7%top quartile
Recent coverage
Recent coverage1 article(s) mentioning MRK
2026-04-30Merck Q1 Earnings Beat Estimates, Narrows 2026 Sales OutlookMerck beats quarterly estimates on strength of Keytruda and new products, narrows outlook.
Observations
IR observations
Mean price target129.46 USD
Median price target133.00 USD
High price target150.00 USD
Low price target100.00 USD
Mean recommendation2.06 (1=strong buy, 5=strong sell)
Strong-buy count7.00
Buy count15.00
Hold count9.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate5.11 USD
Last actual EPS9.18 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Market quoteclose USD 111.26 · shares 2.51B diluted
no public URL
2026-05-01 02:36 UTC#1085723d
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 02:36 UTCJob: 7974ba1a